Biogen Securities Settlement for 2019-2020 Stock Purchases
Biogen agreed to a $25 million settlement over alleged misleading statements to investors. People and entities that bought or acquired its publicly traded common stock from October 22, 2019, through November 5, 2020 may qualify. Payments depend on eligible trading losses and approved claims; a documented claim is required, and final court approval is still pending.
Proof Needed
Claims open·Deadline: January 19, 2027
Who qualifies?
People and entities that bought or otherwise acquired publicly traded Biogen common stock from October 22, 2019, through November 5, 2020. Defendants, specified related people and entities, and valid opt-outs are excluded; gifts, inheritances and short-sale covering purchases do not count toward a payment.
How much could I receive?
A share based on your qualifying trading losses and the other approved claims. The notice estimates average recoveries after fees and expenses of $0.66 per share for July 22-November 5, 2020 purchases and $0.11 for October 22, 2019-July 21, 2020 purchases; these are not promised individual payouts.
Do I need supporting documents?
Yes. Provide broker confirmations, account statements or equivalent records for the listed purchases, sales and beginning and ending holdings. Representatives must also document their authority; send copies and keep the originals.
Do I need a notice ID or PIN?
No settlement notice ID or PIN is required, according to the saved article. The paper claim instead asks for identifying information, including a Social Security or taxpayer identification number, transaction details and a signed certification.
What is the claim deadline?
January 19, 2027. Submit online by 11:59 p.m. Eastern Time, or send a properly addressed first-class mailed claim postmarked by that date; other delivery methods count when the administrator receives them.
How do I claim?
Complete the claim form online through Strategic Claims Services, or sign and mail the paper form with supporting records. Include all required Biogen transactions and holdings; joint claimants must both sign. Institutional and multiple-account representatives must follow the separate spreadsheet-filing instructions.
Yes, if you have qualifying losses in both. Purchases from July 22 through November 5, 2020 share the 80% allocation, while October 22, 2019 through July 21, 2020 purchases share the 20% allocation; each recovery is calculated separately.
Can a qualifying purchase still receive no payment?
Yes. Shares sold on or before November 5, 2020 have no recognized loss. An overall trading gain or break-even result also produces no recovery, and calculated payments below $10 are not distributed.
When will payments be sent?
No payment date is set. Distribution requires final approval, resolution of any appeals, claim processing and the court’s approval to distribute the funds.
Will I be paid if I do nothing?
No. You must submit a valid claim to receive money. Remaining in the class without a claim still binds you to the settlement’s release if it becomes effective.
Get more settlements by email
Get our free weekly roundup of class action settlements and upcoming claim deadlines.
Who is included in the settlement?
The class generally covers people and entities that purchased or otherwise acquired publicly traded Biogen common stock from October 22, 2019 through November 5, 2020. The notice lists exclusions for the defendants, certain family members, officers and directors, related controlled entities, and people who validly opt out.
How is the $25 million fund divided?
The gross fund is divided into two pools because the notice describes different litigation risks for the two purchase periods. Eighty percent, or $20 million, is assigned to purchases from July 22 through November 5, 2020. Twenty percent, or $5 million, is assigned to purchases from October 22, 2019 through July 21, 2020.
How much could I receive?
The notice estimates average recoveries before fees and expenses of about $1.12 per share for the later purchase period and about $0.19 per share for the earlier period. It also estimates about $0.66 and $0.11 per share, respectively, after requested fees and expenses. These are averages, not promised payments. Your recognized loss, trading history, the number of approved claims, and deductions from the fund affect the result. No payment under $10 is issued.
What records must I submit?
Attach broker confirmation slips, broker statements, or equivalent official records for every purchase and sale you list. The form also requests documented holdings at the close of trading on October 21, 2019 and February 2, 2021. Missing official records can cause rejection.
How do I file a claim?
Complete the online form by 11:59 p.m. Eastern Time on January 19, 2027, or mail the signed paper form with a postmark no later than that date. Include the transaction schedule and supporting records. Representative filers handling multiple or institutional accounts must follow the administrator's electronic spreadsheet instructions.
How do I exclude myself?
Mail a signed exclusion request that the administrator receives by January 19, 2027. The request must include the information and transaction details specified in the notice. If you opt out, you receive no settlement payment and cannot object.
How do I object?
File a written objection with the Court and serve the required copies so they are received by February 12, 2027. Include the information, transaction list, grounds, and counsel and prior-objection details required by the notice. You may object only if you remain in the class.
When is the final approval hearing?
The hearing is scheduled for March 5, 2027 at 10:00 a.m. Eastern Time in Courtroom 9 at the federal courthouse in Boston. The Court may hold it by telephone or other virtual means. Attendance is optional.
What happens if I do nothing?
You receive no payment. Unless you validly exclude yourself, you also remain bound by the settlement and release and lose the ability to pursue the released claims separately.
Other Important Dates
Exclusion deadline: 2027-01-19
Objection deadline: 2027-02-12
Final approval hearing: March 5, 2027 at 10:00 a.m. Eastern Time
Hearing location: Courtroom 9, U.S. District Court, 1 Courthouse Way, Boston, Massachusetts 02210
Case Details
Total settlement fund: $25,000,000.00
Case name: Shash v. Biogen Inc., et al.
Case number: 1:21-cv-10479-IT
Court: U.S. District Court for the District of Massachusetts